The size of the Single-use Bioprocessing Market in North America is estimated to worth USD 2.66 billion by 2027 and USD 1.18 billion in 2022, growing at a CAGR of 17.7% from 2022 to 2027.
Single-use bioprocessing technology is a widely used method for the manufacturing of biopharmaceuticals. It is used during the overall procedure of biopharmaceutical production, beginning from buffer and media preparation to biologics shipping. Single-use bioprocessing procedures are processed using different products like manifold assemblies, bioprocess containers and bags, single-use bioreactors, and single-use mixers. They decrease the cost of complex bioproduction processes, such as cleaning, sterilization, and big bioreactors.
Developing life science research, rising demand for disposable biopharmaceuticals, high spending on healthcare, and technological development in the bioprocessing systems are also propelling North America's single-use bioprocessing market.
The expansion of the North America Single-use Bioprocessing Market is expected to be driven by an increase in demand for biopharmaceuticals due to factors such as an increase in the number of chronic diseases and an increase in research and development activities. The rapid use of disposable technologies, reduced risk of product cross-contamination, increased energy efficiency, and fewer floor space requirements are all expected to propel the North American market forward. With the highest share in 2020, North America dominated the single-use bioprocessing market. Disposables have grown popular among contract manufacturing organizations (CMOs), and this region is recognized as a potential market for contract service providers. This factor acts as a drive for domestic and international firms to continue investing in disposables in contract development and manufacturing organizations and manufacturing plants.
The North American government is investing heavily in the development of COVID-19 vaccines, medicines, and diagnostic tests, which is expected to boost demand for single-use bioprocessing and, as a result, overall market growth. Furthermore, automation in the single-use system has led to the incorporation of big data-based machine learning, which will increase product yield. The ability to achieve maximum productivity and efficiency in terms of process and a mainstream approach by many biopharmaceutical manufacturers are all driving the single-use bioprocessing market.
The Single-use Bioprocessing Market is further expected to develop with the rising need for flexible bioprocessing equipment. Furthermore, the introduction of different intelligent bio-manufacturing processes and automation has greatly improved the efficacy of single-use bioprocessing technology. Sensors and disposable probes are in high demand in the biopharmaceutical industry, and demand is expected to continue to rise in the future years. Furthermore, rising geriatric demand for biopharmaceutical medications and biologics patient expiries are two more factors that are propelling the entire regional market forward to a large extent. Furthermore, greater speed and flexibility of these products do not come at a higher cost; rather, keeping total operating costs low will create opportunities for the North America Single-use Bioprocessing Market.
Issues with extractability and leachability of disposable components such as plastic bags and environmental and economic concerns are all restricting the expansion of the single-use bioprocessing market. The expansion of the North America Single-use Bioprocessing Market is claimed to be hampered by government rules imposed in response to environmental concerns. The primary factor that is expected to challenge the growth of the North America Single-use Bioprocessing Market is lack of awareness and issues with high recurring expenses.
This research report has been segmented and sub-segmented the North America Single-use Bioprocessing Market into the following categories:
Regionally, North America Single-use Bioprocessing Market has dominated the global market in 2019 and is predicted to continue its leading position throughout the forecast period. According to the World Health Organization, due to the growing demand for biopharmaceuticals, particularly among the aging population, people aged 60 years and above are expected to reach nearly 2.5 billion by 2050. Less water utilization, high energy efficiency, growing research and development activities, and licensed biologics expire escalate the North American region. U.S and Canada are the two major contributors to this region.
The U.S. market is driven by large-scale biopharmaceutical manufacturing amenities, increasing familiarity of disposables, and ongoing product launches of new SUS in successfully serving domestic and end-users, which is considered to foster the income share in this region.
The Canadian market is the second leading market, followed by the U.S. in North America. It drives the single-use bioprocessing systems market by factors like less production cost, growing consciousness about the consequences of single-use technologies, rising chronic diseases, and the increasing necessity for biopharmaceutical.
KEY MARKET PLAYERS:
Companies playing an active role in leading the North American Single-use Bioprocessing Market profiled in the report are Thermo Fisher Scientific, Danaher Corporation, GE Healthcare (General Electric Company), Sartorius Stedim Biotech S.A, Merck Millipore (Merck Group), 3M Company, Eppendorf AG, Finesse Solutions, Inc., Applikon Biotechnology B.V., and Cesco Bioengineering Co., Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com